Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014

JAMA Oncology

Volumn 2, Issue 7, 2016, Pages 960-961

  Dusetzina, Stacie B ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DRUG COST; ECONOMICS; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; LEGISLATION AND JURISPRUDENCE; NEOPLASMS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DRUG COSTS; HEALTH POLICY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NEOPLASMS;

EID: 85010369862     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0648     Document Type: Article

References (6)

1. Collins, McCaskill Open Senate Investigation into Rx Drug Pricing, Announce Intention to Hold Hearings: Special Committee on Aging. Washington, DC: US Senate; 2015.
2. Neuner JM, Kamaraju S, Charlson JA, et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Cancer Inst. 2015;107(8):djv130.
3. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143-1152.
4. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-311.
5. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539-540.
6. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626-633.